EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis
NCT ID: NCT02648035
Last Updated: 2019-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2016-09-22
2018-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01770834
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
NCT02046616
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT01232569
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
NCT01941095
An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice
NCT02552940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subcutaneous Tocilizumab
Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
Tocilizumab
Subcutaneous Tocilizumab according to approved label.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tocilizumab
Subcutaneous Tocilizumab according to approved label.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Participants who have received TCZ in past treatments.
* Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) of starting treatment TCZ SC.
* Participants with a history of autoimmune disease or of any joint inflammatory disease other than rheumatoid arthritis (RA).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Private Practice Rheumatology, Merantzis
Agrinio, , Greece
Rheumatology Private Practice
Athens, , Greece
General Hospital of Athens KAT, Rheumatology
Athens, , Greece
Rheumatology Private Practice
Athens, , Greece
Private Practice Rheumatology, Stavropoulos
Áno Patísia, , Greece
Rheumatology Private Practice
Chania, , Greece
Private Practice Rheumatology, Papadimitriou
Drama, , Greece
Rheumatology Private Practice
Eleusina, , Greece
ATTIKO Hospital_4th University Internal Medicine Clinic
Haidari, , Greece
Private Practice Rheumatology, Georgiadis
Ioannina, , Greece
Rheumatology Private Practice
Kalithea, Athens, , Greece
Private Practice Rheumatology, Kotrotsios
Karditsa, , Greece
General Hospital of Kavala; Rheumatology
Kavala, , Greece
Rheumatology Private Practice
Kifissia, , Greece
Private Practice Rehumatology, Ziogas
Larissa, , Greece
General Hospital of Mytilini, Rheumatology
Mytilene, , Greece
Private Practice Rheumatology, Trontzas
Néa Smýrni, , Greece
Rheumatology Private Practice
Pátrai, , Greece
Olympion Medical Center of Patras, Internal Medicine Clinic
Pátrai, , Greece
Private Practice Rheumatology, Psaltis
Serres, , Greece
Rheumatology Private Practice
Serres, , Greece
Rheumatology Private Practice
Thessaloniki, , Greece
General Hospital Agios Pavlos
Thessaloniki, , Greece
Rheumatology Private Practice
Thessaloniki, , Greece
Rheumatology Private Practice
Véroia, , Greece
Rheumatology Private Practice
Volos, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML29855
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.